NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer. Rubin EJ, Yeku OO, Morrissey S. N Engl J Med 2024 Sep 15. doi: 10.1056/NEJMe2411492.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rubin EJ, Yeku OO, Morrissey S. NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer. N Engl J Med 2024 Sep 15. doi: 10.1056/NEJMe2411492.
PMID: 39282935